Long-term effect of betaine on risk factors associated with the metabolic syndrome in healthy subjects

European Journal of Clinical Nutrition

Volumn 65, Issue 1, 2011, Pages 70-76

  Schwab, U ^a,b   Alfthan, G ^c   Aro, A ^c   Uusitupa, M ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

betaine; hemostasis; homocysteine; human; lipid

Indexed keywords

BETAINE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MINERAL WATER; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOCRIT; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; NORMAL HUMAN; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SIDE EFFECT; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BETAINE; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; FEMALE; HOMOCYSTEINE; HUMANS; LINEAR MODELS; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; QUESTIONNAIRES; RISK FACTORS; TIME FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 78651094955     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/ejcn.2010.230     Document Type: Article

References (30)

1. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD (2001). Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study. Am J Gastroenterol 96, 2711-2717.
2. Ahotupa M, Ruutu M, Mäntylä E (1996). Simple methods of quantifying oxidation products and antioxidant potential of low density lipoproteins. Clin Biochem 29, 139-144.
3. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hooper J et al (2000). Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet 355, 523-527.
4. Craig SA (2004). Betaine in human nutrition. Am J Clin Nutr 80, 539-549.
5. Detopoulou P, Panagiotakos DB, Antonopoulou S, Pitsavos C, Stefanadis C (2008). Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: The ATTICA study. Am J Clin Nutr 87, 424-430.
6. El-Khairy L, Ueland PM, Nygard O, Refsum H, Vollset SE (1999). Lifestyle and cardiovascular disease risk factors as determinants of total cysteine in plasma: The Hordaland Homocysteine Study. Am J Clin Nutr 70, 1016-1024.
7. Eussen SJPM, Ueland PM, Clarke R, Blom HJ, Hoefnagels WHL, van Staeveren WA et al. (2007). The association of betaine, homocysteine and related metabolites with cognitive function in Dutch elderly people. Br J Nutr 98, 960-968.
8. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M (2008). Homocysteine level and coronary heart disease incidence: A systematic review and meta-analysis. Mayo Clin Proc 83, 1203-1212.
9. Kharbanda KK, Todero SL, Ward BW, Cannella III JJ, Tuma DJ (2009). Betaine administration corrects ethanol-induced defective VLDL secretion. Mol Cell Biochem 327, 75-78.
10. Konstantinova SV, Tell GS, Vollset SE, Nygård O, Bleie Ø, Ueland PM (2008). Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr 138, 914-920.
11. Kwon DY, Jung YS, Kim SJ, Park HK, Park JH, Kim YC (2009). Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats. J Nutr 139, 63-68.
12. Lever M, Bason L, Leaver C, Hayman CM, Chambers ST (1992). Sameday batch measurement of glycine, betaine, carnitine and other betaines in biological material. Anal Biochem 205, 14-21.
13. Lever M, Sizeland PC, Frampton CM, Chambers ST (2004). Short and long-term variation of plasma glycine betaine concentrations in humans. Clin Biochem 37, 184-190.
14. Mar MH, Ridky TW, Garner SC, Zeisel SH (1995). A method for the determination of betaine in tissues using high performance liquid chromatography. J Nutr Biochem 6, 392-398.
15. McGregor DO, Dellow WJ, Robson RA, Level M, George PM, Chambers ST (2002). Betaine supplementation decreases postmethionine hyperhomocysteinemia in chronic renal failure. Kidney Int 61, 1040-1046.
16. Melse-Boonstra A, Holm PI, Ueland PM, Olthof M, Clarke R, Verhoef P (2005). Betaine concentration as a determinant of fasting total homocysteine concentrations and the effect of folic supplementation on betaine concentrations. Am J Clin Nutr 81, 1378-1382.
17. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N et al. (2001). Fasting plasma homocysteine levels in the insulin resistance syndrome: The Framingham offspring study. Diabetes Care 24, 1403-1410.
18. Miglio F, Rovati LC, Santoro A, Setnikar I (2000). Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 50, 722-727.
19. Olthof MR, van Vliet T, Boelsma E, Verhoef P (2003). Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr 133, 4135-4138.
20. Olthof MR, van Vliet T, Verhoef P, Zock PL, Katan MB (2005). Effect of homocysteine-lowering nutrients on blood lipids: Results from four randomised, placebo-controlled studies in healthy humans. PLoS Med 2, e135.
21. Pradhan AD, Ridker PM (2002). Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J 23, 831-834.
22. Rastas M, Seppänen R, Knuts L-R, Hakala P, Karttila V (eds.).(1997). Nutrient Composition of Foods. Publications of the Social Insurance Institution: Helsinki, Finland.
23. Schwab U, Törrönen A, Toppinen L, Alfthan G, Saarinen M, Aro A et al. (2002). Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr 76, 961-967.
24. Schwab U, Törrönen A, Meririnne E, Saarinen M, Alfthan G, Aro A et al. (2006). Orally administered betaine has an acute and dosedependent effect on serum betaine and plasma homocysteine concentrations in healthy humans. J Nutr 136, 34-38.
25. Schwahn BC, Wang XL, Mikael LG, Wu Q, Cohn J, Jiang H et al. (2007). Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia. Atherosclerosis 195, e100-e107.
26. Singh RH, Kruger WD, Wang L, Pasquali M, Elsas II LJ (2004). Cystathionine beta-synthase deficiency: Effects of betaine supplementation after methionine restriction in B6-nonresponsive homocystinuria. Genet Med 6, 90-95.
27. Steenge GR, Verhoef P, Katan MB (2003). Betaine supplementation lowers plasma homocysteine in healthy men and women. J Nutr 133, 1291-1295.
28. Ubbink JB, Vermaak WJH, Bissbort S (1991). Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr 565, 441-446.
29. Ueland PM, Holm PI, Hustad S (2005). Betaine: A key modulator of one-carbon metabolism and homocysteine status. Clin Chem Lab Med 43, 1069-1075.
30. Wilcken DE, Wilcken B, Dudman NP, Tyrell PA (1983). Homocystinuria- the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med 309, 448-453.